The M&A team advised Centerview Partners as exclusive financial advisor to Alpine Immune Sciences (Nasdaq: ALPN) in its definitive agreement with Vertex Pharmaceuticals (Nasdaq: VRTX) to be acquired for $65 per share or approximately $4.9 billion in cash. A subsidiary of Vertex will commence a cash tender offer to purchase all outstanding shares of Alpine common stock. The transaction is expected to close in the second quarter of 2024, subject to certain conditions, including the tender of a majority of the outstanding shares of Alpine common stock and the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors.
Alpine is committed to leading a new wave of immune therapeutics. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- or best-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.
Centerview Partners, based in New York and with offices in London, Paris, San Francisco and Menlo Park, operates an international investment banking advisory practice across all sectors, specializing in independent advice and other client services capitalizing on the experience of its principals. Since its founding in 2006, the firm has advised clients on nearly $4 trillion in transactions.
The Goodwin team was led by Stuart Cable, James Matarese, Blake Liggio and James Ding.
For additional details on the acquisition, please read the press release.